Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...
Sage Therapeutics Inc (SAGE) reports significant prescription growth for ZURZUVAE, despite a net loss and strategic ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
Canaccord lowered the firm’s price target on Sage Therapeutics (SAGE) to $8 from $9 and keeps a Hold rating on the shares. The firm said they ...
Sage Therapeutics and partner Biogen equally shares profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...
--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... Collaboration revenues represent 50% of the net revenues recorded when Biogen ships ZURZUVAE to the distributors. For the year ended December ...